Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma

Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma

Background Randomized trials evaluating programmed cell death protein 1 (PD-1) inhibitors in metastatic melanoma either permitted treatment for 2 years (pembrolizumab) or more (nivolumab). The optimal duration of therapy is currently unknown due to limited data, and shorter therapies may be effectiv...

Full description

Bibliographic Details
Main Authors:	Siwen Hu-Lieskovan, Rebecca Pokorny, Jordan P McPherson, Carolyn Luckett, Benjamin Newell Voorhies, Daniel S Sageser, Jocelyn Wallentine, Zachary Tolman, Umang Swami
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-01-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/9/1/e001781.full

Similar Items

Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events
by: Umang Swami, et al.
Published: (2019-01-01)

Discontinuous ‘PD’ Control of Thermal Processes
by: William K. Roots MSc, PhD, WhF, FIEE, Sen Mem IEEE, MIE Aust, et al.
Published: (1969-05-01)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
by: Funakoshi, Y., et al.
Published: (2022)

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
by: Angel Garcia-Diaz, et al.
Published: (2017-05-01)

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)
by: Motoko Tachihara, et al.
Published: (2018-10-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
by: Justin C. Moser, et al.
Published: (2019-12-01)

Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies
by: Umang Swami, et al.
Published: (2020-10-01)

Facilitators and Impediments for Elective Music and Sport in Adolescent Males
by: Simone Waters, et al.
Published: (2014-04-01)

Modeling, Discontinuous Galerkin Approximation and Simulation of the 1-D Compressible Navier Stokes Equations
by: Grigorian, Zachary
Published: (2019)

The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment
by: Katie Hudson, et al.
Published: (2020-10-01)

Eribulin in Cancer Treatment
by: Umang Swami, et al.
Published: (2015-08-01)

PD-1/PD-L1 immunotherapy blockade in solid tumors: role of PD-1/PD-L1 in cancer disease progression
by: Li, Vivian
Published: (2021)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
by: Vishwanatha R. A. P. Reddy, et al.
Published: (2019-12-01)

The PD-1:PD-L1 axis in Inflammatory Arthritis
by: Mary Canavan, et al.
Published: (2021-01-01)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
by: Jakub Litak, et al.
Published: (2019-10-01)

PD-1/PD-L1 Inhibitors in Cervical Cancer
by: Yuncong Liu, et al.
Published: (2019-02-01)

The Role of PD-1 in Acute and Chronic Infection
by: Jil M. Jubel, et al.
Published: (2020-03-01)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
by: Ana Bocanegra, et al.
Published: (2020-08-01)

Ocular adverse events in PD-1 and PD-L1 inhibitors
by: James Murray, et al.
Published: (2021-07-01)

Targeting the PD-1/PD-L1 Axis in Human Vitiligo
by: Marcella Willemsen, et al.
Published: (2020-11-01)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
by: Tomas Jelinek, et al.
Published: (2018-11-01)

PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
by: Hideto Tamura, et al.
Published: (2020-04-01)

State of PD-L1 and PD-1 screening and therapy in NSCLC
by: Frido Bruehl, et al.
Published: (2018-04-01)

Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
by: Ming Yi, et al.
Published: (2018-08-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
by: Elizabeth Ahern, et al.
Published: (2018-06-01)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
by: Bogang Wu, et al.
Published: (2018-11-01)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
by: Hyun Tae Lee, et al.
Published: (2017-07-01)

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
by: Rosemarie Tremblay-LeMay, et al.
Published: (2018-03-01)

Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
by: Yunlong Zhao, et al.
Published: (2018-07-01)

Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility
by: Chenyue Qian, et al.
Published: (2018-01-01)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
by: Maureen L. Drakes, et al.
Published: (2018-05-01)

Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors
by: Jiangang Sun, et al.
Published: (2020-09-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
by: Bin Zhao, et al.
Published: (2020-07-01)

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
by: Xueping Wang, et al.
Published: (2020-05-01)

The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface
by: Matyas Meggyes, et al.
Published: (2019-02-01)

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
by: Solène-Florence Kammerer-Jacquet, et al.
Published: (2019-04-01)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
by: Chen Q, et al.
Published: (2018-08-01)